Today @AltoNeuro began trading on the @NYSE under the ticker $ANRO. I founded Alto out of the desire to give patients better treatment options than those that are currently available. Today we take one step closer to our goal of making #PrecisionPsychiatry a reality.

RT @AltoNeuro: Our CEO, @AmitEtkin, will discuss Alto’s recent corporate updates during upcoming investor conferences. Learn more: https://….

Excited to have Ray join the @AltoNeuro board!.

RT @AltoNeuro: We’re excited to welcome Raymond Sanchez, M.D., to Alto’s Board of Directors, a highly accomplished executive with a strong….

RT @AltoNeuro: Last week, our CEO @AmitEtkin joined #NYSEFloorTalk to share how Alto is advancing a new era of precision psychiatry and how….

Here's the link to the full interview on the @NYSE floor from last week at the AI x Bio summit. It was a pleasure to share what we are up to @AltoNeuro! A lot of exciting potential ahead.

Was a lot of fun sharing the @AltoNeuro story and updates on the iconic floor of the @NYSE. A lot of clinical readouts to come over the next two years!.

RT @NYSE: LIVE on NYSE TV 🎙️ Hear top economic data from @commonsensebull. @AmitEtkin of @AltoNeuro shares how they are utilizing AI at NYS….

It was a pleasure to speak with @BiotechTV today at the @NYSE!.

Important PAX-D publication today! I highlight the findings and how ALTO-207 builds on that success in the video below.

Congrats to the @OxPsychiatry team, Mike Browning and the PAX-D investigators on a landmark finding demonstrating striking efficacy of pramipexole in TRD!.

RT @AltoNeuro: We’re excited to highlight that data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depres….

RT @OxHealthBRC: 📣A Parkinson’s drug, #pramipexole, shows promise for #treatmentresistantdepression. In an @oxpsych led and @NIHRresearch s….

RT @AltoNeuro: Today we announced the acquisition of a novel dopamine agonist portfolio, adding a late-stage readout in treatment resistant….

RT @AltoNeuro: Today, our CEO, @AmitEtkin, will participate in a panel discussion moderated by @rleuty_biotech at the Bay Area Biotech Foru….

RT @AltoNeuro: Today, we reported our Q1 2025 financial results and key business highlights. Read more in our press release here: https://t….

We remain on track to report findings from the first clinical study of ALTO-203 in 1H 2025, which examines its symptomatic, cognitive and other pharmacodynamic effects in depressed patients with anhedonia given single doses of the drug. Kudos to the @altoneuro team!.

This of course is just one aspect of what H3 receptors regulate, and we expect that ALTO-203’s effects on dopamine could improve other aspects of brain function such as cognition (long related to dopamine, and of interest in studies of H3 inverse agonists).

These findings provide further support for the idea that ALTO-203 has properties unique from the one approved H3 drug (pitolisant), one of which is relevant for motivated behavior like reward-seeking/anhedonia.

We induced anhedonia in rodents by giving them a drug (AMPT) that depletes dopamine. We found that specific doses of ALTO-203 can rescue this deficit, but that pitolisant cannot.

What ALTO-203 appears to do uniquely from other H3 inverse agonists, is increase dopamine in the reward system, not just in the cortex as other drugs like pitolisant do. We therefore tested whether ALTO-203 had unique effects on dopamine-related behavior like anhedonia.